Chang leads assay and applications development at Takara Bio, driving the commercialization of novel spatial genomics products. She has extensive experience in single-cell multiomics technologies and ...

FACE binds to CD71 on the T‑cell surface in CAR T cell preparation, and post-infusion, the same FACE molecules attach to CD71 on leukemia cells.

Researchers from the Massachusetts Institute of Technology (MIT) Jameel Clinic for Machine Learning in Health have announced the open-source release of Boltz-2, which now predicts molecular binding ...

When the eye’s drainage system clogs, intraocular pressure (IOP) builds up and causes damage. The pressure can lead to glaucoma and vision loss. Researchers headed by a team at Duke University School ...

Over the past decade, however, a wave of technological advances has begun to expand the druggable proteome. These include covalent inhibitors (such as sotorasib), chemical proteomics, and AI-enabled ...

In intensified bioprocessing, the engineered CHO host supports higher titers and long culture duration in continuous perfusion.

Therapeutic developers are increasingly rebuilding their workflows around AI to bring drugs to patients faster.

Qure shares finished the regular trading week down only 9% despite the FDA’s hard-line stance and public criticism against the company’s Huntington’s disease (HD) gene therapy candidate AMT-130.

Non-CHO cell expression systems gain traction as faster, more flexible alternatives for biologics manufacturing.

With clinical data beginning to emerge, big pharma is signaling its belief that in vivo CAR generation is the next immunotherapy breakthrough.

Enzene’s New Jersey facility offers efficient, fully continuous or hybrid vat production within a modular framework.

As climate pressure mounts, new platforms tackle delivery, regulation, trait stacking, and data bottlenecks limiting agricultural genome editing.